Tags

Type your tag names separated by a space and hit enter

CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease.
Neurology. 2012 Mar 06; 78(10):709-19.Neur

Abstract

OBJECTIVE

Measures of neuronal damage/dysfunction are likely good surrogates for disease progression in Alzheimer disease (AD). CSF markers of neuronal injury may offer utility in predicting disease progression and guiding prognostic and outcome assessments in therapeutic trials. Visinin-like protein-1 (VILIP-1) has demonstrated potential utility as a marker of neuronal injury. We here investigate the utility of VILIP-1 and VILIP-1/Aβ42 in predicting rates of cognitive decline in early AD.

METHODS

Individuals with a clinical diagnosis of very mild or mild AD (n = 60) and baseline CSF measures of VILIP-1, tau, p-tau181, and Aβ42 were followed longitudinally for an average of 2.6 years. Annual assessments included the Clinical Dementia Rating (CDR), CDR-sum of boxes (CDR-SB), and global composite scores. Mixed linear models assessed the ability of CSF biomarker measures to predict rates of cognitive decline over time.

RESULTS

Baseline CSF VILIP-1 and VILIP-1/Aβ42 levels predicted rates of future decline in CDR-SB and global composite scores over the follow-up period. Individuals with CSF VILIP-1 ≥560 pg/mL (corresponding to the upper tercile) progressed much more rapidly in CDR-SB (1.61 boxes/year; p = 0.0077) and global scores (-0.53 points/year; p = 0.0002) than individuals with lower values (0.85 boxes/year and -0.15 points/year, respectively) over the follow-up period. CSF tau, p-tau181, tau/Aβ42, and p-tau181/Aβ42 also predicted more rapid cognitive decline in CDR-SB and global scores over time.

CONCLUSION

These findings suggest that CSF VILIP-1 and VILIP-1/Aβ42 predict rates of global cognitive decline similarly to tau and tau/Aβ42, and may be useful CSF surrogates for neurodegeneration in early AD.

Links

PMC Free PDF
PMC Free Full Text
Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Tarawneh R
Department of Neurology, Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA.
Lee JM
No affiliation info available
Ladenson JH
No affiliation info available
Morris JC
No affiliation info available
Holtzman DM
No affiliation info available

MeSH

AgedAged, 80 and overAlzheimer DiseaseCognitionCognition DisordersDisease ProgressionFemaleHumansMaleMiddle AgedNeurocalcintau Proteins

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22357717

Citation

Tarawneh, R, et al. "CSF VILIP-1 Predicts Rates of Cognitive Decline in Early Alzheimer Disease." Neurology, vol. 78, no. 10, 2012, pp. 709-19.
Tarawneh R, Lee JM, Ladenson JH, et al. CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease. Neurology. 2012;78(10):709-19.
Tarawneh, R., Lee, J. M., Ladenson, J. H., Morris, J. C., & Holtzman, D. M. (2012). CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease. Neurology, 78(10), 709-19. https://doi.org/10.1212/WNL.0b013e318248e568
Tarawneh R, et al. CSF VILIP-1 Predicts Rates of Cognitive Decline in Early Alzheimer Disease. Neurology. 2012 Mar 6;78(10):709-19. PubMed PMID: 22357717.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease. AU - Tarawneh,R, AU - Lee,J-M, AU - Ladenson,J H, AU - Morris,J C, AU - Holtzman,D M, Y1 - 2012/02/22/ PY - 2012/2/24/entrez PY - 2012/2/24/pubmed PY - 2012/7/7/medline SP - 709 EP - 19 JF - Neurology JO - Neurology VL - 78 IS - 10 N2 - OBJECTIVE: Measures of neuronal damage/dysfunction are likely good surrogates for disease progression in Alzheimer disease (AD). CSF markers of neuronal injury may offer utility in predicting disease progression and guiding prognostic and outcome assessments in therapeutic trials. Visinin-like protein-1 (VILIP-1) has demonstrated potential utility as a marker of neuronal injury. We here investigate the utility of VILIP-1 and VILIP-1/Aβ42 in predicting rates of cognitive decline in early AD. METHODS: Individuals with a clinical diagnosis of very mild or mild AD (n = 60) and baseline CSF measures of VILIP-1, tau, p-tau181, and Aβ42 were followed longitudinally for an average of 2.6 years. Annual assessments included the Clinical Dementia Rating (CDR), CDR-sum of boxes (CDR-SB), and global composite scores. Mixed linear models assessed the ability of CSF biomarker measures to predict rates of cognitive decline over time. RESULTS: Baseline CSF VILIP-1 and VILIP-1/Aβ42 levels predicted rates of future decline in CDR-SB and global composite scores over the follow-up period. Individuals with CSF VILIP-1 ≥560 pg/mL (corresponding to the upper tercile) progressed much more rapidly in CDR-SB (1.61 boxes/year; p = 0.0077) and global scores (-0.53 points/year; p = 0.0002) than individuals with lower values (0.85 boxes/year and -0.15 points/year, respectively) over the follow-up period. CSF tau, p-tau181, tau/Aβ42, and p-tau181/Aβ42 also predicted more rapid cognitive decline in CDR-SB and global scores over time. CONCLUSION: These findings suggest that CSF VILIP-1 and VILIP-1/Aβ42 predict rates of global cognitive decline similarly to tau and tau/Aβ42, and may be useful CSF surrogates for neurodegeneration in early AD. SN - 1526-632X UR - https://www.unboundmedicine.com/medline/citation/22357717/CSF_VILIP_1_predicts_rates_of_cognitive_decline_in_early_Alzheimer_disease_ L2 - http://www.neurology.org/cgi/pmidlookup?view=long&pmid=22357717 DB - PRIME DP - Unbound Medicine ER -